Abstract:IntroductionUveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, and the main treatment for UM is currently surgery and plaque brachytherapy. UM is highly susceptible to metastasis, which eventually occurs in nearly half of all patients; once metastasis occurs, patients have a poor prognosis and the condition is difficult to treat. Therefore, the identification of new and effective UM biomarkers is vital for the application of therapeutic strategies. Immunogenic cell death (ICD) is a type of regulatory cell death that activates adaptive immune responses and generates long-term immunological memory. ICD can promote antitumor immunity, which may be a potential immunotherapeutic strategy for UM. MethodsThe data of UM from the Cancer Genome Atlas (TCGA) was used as a training set and the data from Gene Expression Omnibus (GEO) was used as a validation set. To determine the expression pattern of ICD-related genes in UM, survival analysis and difference analysis was conducted. The ICD-related risk signature was constructed by employing the least absolute shrinkage and selection operator (LASSO) Cox regression. Subsequently, immune profile and somatic mutation analysis were performed. In addition, cell experiments were performed to verify the role of immunogenic cell death-related genes in UM. ResultsIn this study, we analyzed the relationship between ICD-related gene expression and UM patient prognosis, somatic mutations, and the tumor immune microenvironment. Importantly, we constructed a 5-gene ICD-related risk signature and confirmed it as a novel prognostic biomarker in UM patients. We found that the high-risk group had more immune cell infiltration and a worse prognosis than the low-risk group. In cellular experiments, we confirmed the high expression of FOXP3 inMUM2B andOCM-1A cell lines and that knockdown of FOXP3 markedly inhibited the proliferation of UM tumor cells. DiscussionICD-related genes play a critical role in the tumor immune microenvironment. Our results may contribute to the development of effective immunotherapies.

Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment

Uveal melanoma: Recent advances in immunotherapy

Recent Advances and Challenges in Uveal Melanoma Immunotherapy

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

New immunotherapy approaches as the most effective treatment for uveal melanoma

Identifying biomarkers and novel therapeutic targets in uveal melanoma

The Prognostic Landscape of Adaptive Immune Resistance Signatures and Infiltrating Immune Cells in the Tumor Microenvironment of Uveal Melanoma.

Development of New Therapeutic Options for the Treatment of Uveal Melanoma

Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions

Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

The Current State of Systemic Therapy of Metastatic Uveal Melanoma

Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study

Uveal melanoma: molecular-genetic mechanisms of arising and the therapeutic approaches

Uveal melanoma: laboratory advances and new frontiers in patient care

Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives

Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma

[Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches]

Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression

Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases

The roles of genetic mutation and cytokines/chemokines in immune response and their association with uveal melanoma patient outcome